ECHELON-1: brentuximab vedotin replacing bleomycin in first-line chemotherapy for advanced Hodgkin lymphoma
Swapping bleomycin for the CD30 antibody-drug conjugate brentuximab vedotin modestly improved disease control in advanced Hodgkin lymphoma and, at six years, improved survival.
ECHELON-1 randomised 1334 patients with previously untreated stage III or IV classical Hodgkin lymphoma to brentuximab vedotin plus doxorubicin, vinblastine and dacarbazine (A+AVD) or standard ABVD for six cycles. The primary endpoint was modified PFS by independent review. At two years modified PFS was 82.1% versus 77.2% (hazard ratio 0.77). A+AVD caused more peripheral neuropathy (67% versus 43%) and febrile neutropenia (19% versus 8%) but eliminated bleomycin lung toxicity. The six-year update (Ansell et al., NEJM 2022) showed an overall survival benefit: 93.9% versus 89.4% (hazard ratio 0.59), the first OS improvement in front-line advanced Hodgkin lymphoma.
- 1334 patients with stage III-IV classical Hodgkin lymphoma; A+AVD vs ABVD.
- 2-year modified PFS 82.1% vs 77.2%; hazard ratio 0.77.
- Peripheral neuropathy 67% vs 43%; febrile neutropenia 19% vs 8%; pulmonary toxicity lower with A+AVD.
- 6-year overall survival 93.9% vs 89.4%; hazard ratio 0.59.
- Fewer second malignancies and fewer patients needing subsequent therapy with A+AVD.
ECHELON-1 made a targeted antibody-drug conjugate part of first-line Hodgkin therapy and eventually showed that this saves lives, not just relapses. It set the reference arm against which nivolumab-AVD (SWOG S1826) and BrECADD (HD21) were later compared. Neuropathy is the main price and needs proactive dose modification.
- Modified PFS was a novel composite endpoint counting incomplete response followed by further therapy as an event.
- Early absolute benefit was small (about 5 points) and OS emerged only with long follow-up.
- Excluded early-stage disease; older patients (over 60) had high toxicity with A+AVD.
- Cost of brentuximab restricts use in lower-income settings.